Skip to content

Red flags and safety concerns

TL;DR — Four categories of harm attach to IBS: missing organic disease, harming patients with IBS drugs, harming patients with IBS diets, and the harms of the label itself. Alarm features perform poorly individually: pooled across 31 studies and 45,100 patients, sensitivity for colorectal cancer ranges from 12.4% (weight loss) to 49% (rectal bleeding), with specificity 69.8–91.9%; only rectal bleeding (number needed to scope 5.3) and anaemia (6.7) are practical triggers for colonoscopy (Frazzoni 2023, PMID 36241197). Conversely, colonoscopy in patients without alarm features had zero yield in the only prospective Rome IV series (0/11; Asghar 2022, PMID 32882424). Eluxadoline carries the field's most serious drug harm: sphincter-of-Oddi spasm in 10/1,839 treated patients (0.5%), every case in a patient without a gallbladder, and pancreatitis in 16.4% of 597 post-marketing adverse-event reports with 53 hospitalisations and two reported fatalities (Cash 2017, PMID 27922029; Gawron 2018, PMID 28804032). Alosetron was withdrawn in 2000 for ischaemic colitis and returned only under a restricted prescribing programme (Lewis 2010, PMID 20136586); its number needed to harm for adverse-event discontinuation is 14, the highest of any IBS drug (Busam 2026, PMID 40471839). Suicidality is a real and under-recognised endpoint: 38% of tertiary-care IBS patients had contemplated suicide because of their bowel symptoms, versus 16% in secondary care, 4% in primary care and 15% in active inflammatory bowel disease (Miller 2004, PMID 15625650) — and depression scores did not account for all the variance. Long-term strict FODMAP restriction is explicitly advised against by the trialists who measured its microbial cost (Wilson 2020, PMID 32433273). Finally, an IBS label can precede a missed diagnosis: ovarian cancer incidence is raised at 3 months (HR 1.71, 1.08–2.70) and 6 months (HR 1.43, 1.06–1.93) after an index IBS diagnosis, but not beyond 8 months (Shin 2025, PMID 41081454). This page is research knowledge, not clinical advice.

1. Missing organic disease

Alarm features, measured

Feature Sensitivity for CRC Specificity Number needed to scope
Rectal bleeding 49% 69.8% 5.3
Anaemia — — 6.7
Change in bowel habit — — not practical alone
Weight loss 12.4% 91.9% not practical alone

Thirty-one studies, 45,100 patients, colonoscopy as reference standard; CRC prevalence across studies ranged 0.2–22%. The authors' conclusion: alarm features have variable accuracy given population heterogeneity; "rectal bleeding and anemia are the most practical to select patients for colonoscopy" and features should be integrated into a comprehensive evaluation rather than used alone (Frazzoni 2023, PMID 36241197). Rectal bleeding alone has its own diagnostic-value literature (Tong 2014, PMID 24568444).

What the yield data say about who to investigate

Situation Yield Source
IBS without alarm features, prospective Rome IV series 0 of 11 colonoscopies abnormal Asghar 2022, PMID 32882424
IBS without alarm symptoms or age <40 CRC <0.1% Wu 2023, PMID 36168183
IBS with alarm symptoms CRC 2.47% vs 0.11% (RD 2.57%, 0.37–4.78); IBD 8.86% vs 4.25% (RD 10.75%, 4.81–16.68) Wu 2023, PMID 36168183
Diarrhoeal functional bowel disorders referred for colonoscopy Organic disease ~17%; microscopic colitis 5.7% vs 0% in constipation phenotypes Asghar 2022, PMID 32882424
First-time IBS diagnosis, national registry Microscopic colitis 2.9% vs 1.7% in controls (aOR 1.77, 1.61–1.95); IBD, polyps, CRC and coeliac all less common than in controls Staller 2021, PMID 34420846

The commonest genuinely missed diagnosis in the diarrhoea phenotype is microscopic colitis, and it is missed for want of biopsies: one in four chronic-diarrhoea patients undergoing colonoscopy had no colonic biopsies taken (Asghar 2022, PMID 32882424). Detail on differential-diagnosis-and-exclusion.

Diagnoses that can hide behind the label

Condition Signal Source
Coeliac disease Biopsy-proven in 2% (2–3) of criteria-defined IBS; OR 4.42 (2.82–6.92) for positive serology vs controls Shiha 2025, PMID 40493044
Bile acid diarrhoea 28.1% (22.6–34.0) of IBS-D by SeHCAT <10%; treatable Slattery 2015, PMID 25913530; Dilmaghani 2025, PMID 41090475
Microscopic colitis 2.35% pooled at colonoscopy; enriched in IBS vs controls Wu 2023, PMID 36168183; Staller 2021, PMID 34420846
Exocrine pancreatic insufficiency 5–6.1% of IBS-D by faecal elastase <100 µg/g Leeds 2010, PMID 19835990; Olmos 2022, PMID 35704255
Ovarian cancer HR 1.71 (1.08–2.70) at 3 months and 1.43 (1.06–1.93) at 6 months after index IBS diagnosis; not beyond 8 months — a misdiagnosis signal, not causation Shin 2025, PMID 41081454
Crohn's disease Median diagnostic delay 8 months (range 0–324) in 83 consecutively diagnosed patients Maconi 2015, PMID 26004215
Giardiasis Active infection is a differential; sequelae are a cause Camilleri 2025, PMID 39480027; Hanevik 2014, PMID 25115874

The other direction: over-investigation and unnecessary surgery

Exhaustive investigation "is unnecessary, and may be counterproductive" (Black 2020, PMID 32133113), and the randomised comparison found a positive diagnostic strategy safe over five years with no coeliac disease and no gastrointestinal or gynaecological cancers missed in either arm (Engsbro 2021, PMID 33029843). Protecting patients with IBS "from the risks and costs of unnecessary surgery" has been an explicit concern in the literature for nearly two decades (Longstreth 2007, PMID 17440179).

2. Drug harms

Drug Harm Quantification Source
Eluxadoline Sphincter-of-Oddi spasm; pancreatitis 10/1,839 (0.5%) SOS events, all in patients without a gallbladder, 8 on the higher dose, all within 1 week, all resolving on discontinuation; 5 further adjudicated pancreatitis events, 3 with heavy alcohol use. Registration trials: pancreatitis in 5/1,666 (0.3%). Post-marketing: 16.4% of 597 FAERS reports were pancreatitis, 53 requiring hospitalisation, vs 0.2–0.5% for loperamide, diphenoxylate, oxycodone and rifaximin; two reported fatalities Cash 2017, PMID 27922029; Lembo 2016, PMID 26789872; Gawron 2018, PMID 28804032
Alosetron Ischaemic colitis; severe constipation complications Withdrawn November 2000; reintroduced 2002 under a Risk Management Plan with restricted indication and a Prescribing Program; use has remained very limited. NNH for adverse-event discontinuation 14 — the highest measured for any IBS drug Lewis 2010, PMID 20136586; Lucak 2010, PMID 21180598; Busam 2026, PMID 40471839
Tegaserod Cardiovascular ischaemic events Two external adjudications of 18,645 patients: coronary/cerebrovascular ischaemic events 7 (0.06%) vs 1 (0.01%), OR 4.24 (95% CI 0.52–34.74), p=0.273. All tegaserod cases had ≥1 cardiovascular risk factor. Licensed only for women <65 with no ischaemic history and ≤1 risk factor Lacy 2022, PMID 34048937
Tenapanor Diarrhoea NNH 16 (p<0.01); discontinuation for diarrhoea 6.5% vs 0.7% placebo Busam 2026, PMID 40471839; Chey 2021, PMID 33337659
Linaclotide Diarrhoea NNH 35; discontinuation for diarrhoea 4.5% vs 0.2% placebo Busam 2026, PMID 40471839; Chey 2012, PMID 22986437
Tricyclics Anticholinergic effects, withdrawal NNH 24 (p<0.01); adverse events RR 1.59 (1.26–2.06) vs placebo; ATLANTIS adverse-event withdrawals 12.9% vs 8.7% Busam 2026, PMID 40471839; Black 2020, PMID 31859183; Wright-Hughes 2024, PMID 39397570
Rifaximin — Safest IBS pharmacotherapy studied: NNH negative and non-significant; no clinically significant change in stool microbial antibiotic sensitivity on repeat courses Busam 2026, PMID 40471839; Pimentel 2017, PMID 28589238

A limitation of the NNH metric: it counts discontinuation for adverse events and therefore misses rare catastrophic harms. Eluxadoline's pancreatitis and alosetron's ischaemic colitis are exactly the events it does not capture, and they are the reason both drugs carry restrictions.

Opioids. Opioid receptor pharmacology is central to eluxadoline's action and its harm (Corsetti 2019, PMID 30863534; Hughes 2016, PMID 27469369), and opioid-induced bowel dysfunction produces motility dysfunction and visceral hyperalgesia through mechanisms that are partly opioid-receptor-independent (Lin 2021, PMID 33908261). Centrally mediated abdominal pain syndrome — including narcotic bowel syndrome — is a recognised and distinct entity (Fukudo 2026, PMID 41692277; Keefer 2016, PMID 27144628).

3. Dietary harms

Concern Evidence Source
Microbial cost of strict FODMAP restriction Reduced faecal Bifidobacterium, Actinobacteria (1.9% and 1.8% vs 4.2% control) and butyrate (387.3 and 346.0 vs 609.2); "strict long-term use should not be advised" Wilson 2020, PMID 32433273
Luminal environment Higher faecal pH (7.37 vs 7.16, p=0.001), lower total bacterial abundance (p<0.001), altered composition Halmos 2015, PMID 25016597
Nutritional adequacy after reintroduction Not compromised in either adapted-FODMAP or habitual groups at long-term follow-up; higher cost (p<0.001) and more impact on social eating (p<0.01) O'Keeffe 2018, PMID 28707437
Disordered eating Framed as a contested "grey area" between adaptive restriction and eating pathology; both over- and under-pathologising are risks. No cohort quantifying incident eating-disorder diagnoses after low-FODMAP instruction was retrievable in this session's searches (searched 2026-09-02) Scarlata 2025, PMID 39681226; Atkins 2023, PMID 36782302
Unnecessary lactose exclusion Self-reported lactose intolerance has only moderate accuracy against breath testing; routine lactose-free diets are not supported Pop 2024, PMID 39255349
Gluten exclusion before coeliac testing Coeliac serology and biopsy become unreliable off gluten; coeliac disease must be excluded first Shiha 2025, PMID 40493044; Black 2020, PMID 32133113

The reintroduction data cut both ways: nutritional adequacy was preserved because patients reintroduced FODMAPs to tolerance (mean intake 20.6 ± 14.9 g/day in the adapted group; O'Keeffe 2018, PMID 28707437), and blinded reintroduction shows most patients react to only 2.5 ± 2 FODMAPs (Van den Houte 2024, PMID 38401741). Restriction beyond that is unnecessary as well as costly. See dietary-therapy.

4. Psychological safety

Suicidality. In a comparison of 100 tertiary-care IBS patients, 100 secondary-care, 100 primary-care and 100 patients with active inflammatory bowel disease, participants were asked whether they had contemplated or attempted suicide specifically because of their bowel problem (Miller 2004, PMID 15625650):

Group Contemplated suicide because of bowel symptoms
Tertiary-care IBS 38%
Secondary-care IBS 16%
Primary-care IBS 4%
Active inflammatory bowel disease 15%

Five tertiary IBS patients and one IBD patient had attempted suicide for gastrointestinal reasons. Mean depression scores did not exceed the threshold of 10 in the secondary-care group contemplating suicide (9.7) and were only just above it in the tertiary group (11.7) — i.e. depression did not account for all the variance. The authors identified hopelessness from symptom severity, interference with life and inadequacy of treatment as the crucial issues. More recent work has examined the association with depression and anxiety (Li 2026, PMID 42034841) and used Mendelian randomisation to probe causality between IBS and suicide attempt (Deng 2025, PMID 40320944).

Practical consequences visible in the trial literature: ATLANTIS excluded participants with suicidal ideation at entry (Ford 2023, PMID 37858323), and IBS trials have developed explicit suicidal-risk assessment protocols using PHQ-9 (Wileman 2024, PMID 38997767).

Invalidation. Symptom invalidation in contested illnesses including IBS is linked to shame, suicidality, healthcare-system avoidance and diagnostic delay across 151 qualitative reports and 11,307 individuals (Bontempo 2025, PMID 40310228). This is a safety issue, not only an experience issue: healthcare avoidance and diagnostic delay are the mechanisms by which it becomes one. See quality-of-life-and-stigma.

5. Situations requiring re-evaluation

Drawn from the yield and risk-factor data above rather than from consensus:

Trigger Rationale
New rectal bleeding or anaemia Only alarm features with a practical number needed to scope (5.3 and 6.7) (Frazzoni 2023, PMID 36241197)
Onset or change in symptoms at older age CRC and microscopic colitis yield rise with age (Wu 2023, PMID 36168183; Staller 2021, PMID 34420846)
Chronic diarrhoea without colonic biopsies Microscopic colitis is the commonest missed diagnosis in this phenotype (Asghar 2022, PMID 32882424)
IBS-D not responding to standard therapy Bile acid diarrhoea (28.1%) and exocrine pancreatic insufficiency (5–6.1%) are treatable and commonly untested (Slattery 2015, PMID 25913530; Olmos 2022, PMID 35704255)
Persisting symptoms after an enteric infection Post-infectious IBS is common but so is missed persisting infection (Klem 2017, PMID 28069350; Camilleri 2025, PMID 39480027)
Recent IBS label in a woman with new abdominal or pelvic symptoms Ovarian cancer signal confined to the first ~6 months after diagnosis (Shin 2025, PMID 41081454)
Escalating opioid use with worsening pain Opioid-induced bowel dysfunction and centrally mediated pain syndromes (Fukudo 2026, PMID 41692277; Lin 2021, PMID 33908261)
Expressed hopelessness about symptoms Suicidal ideation rises steeply with care level and is not fully explained by depression (Miller 2004, PMID 15625650)

Open questions

  • What is the true miss rate for microscopic colitis, given that a quarter of eligible patients are not biopsied (Asghar 2022, PMID 32882424)?
  • Should eluxadoline remain on the market? 16.4% of its post-marketing adverse-event reports were pancreatitis (Gawron 2018, PMID 28804032) against an NNT of about 8 (Brenner 2019, PMID 31356229).
  • Is tegaserod safe in the licensed population, or merely not demonstrably unsafe? OR 4.24 with 95% CI 0.52–34.74 (Lacy 2022, PMID 34048937).
  • Has the 38% tertiary-care suicidal-ideation figure been replicated since 2004 (Miller 2004, PMID 15625650)? No comparable multi-tier replication was retrievable in this session's searches.
  • Does long-term FODMAP restriction cause clinically meaningful harm? The microbial changes are documented (Wilson 2020, PMID 32433273) and their consequences are not.
  • Does restrictive dietary therapy precipitate eating disorders? The question is posed and unquantified (Scarlata 2025, PMID 39681226).
  • Can an alarm-feature score outperform individual features? Frazzoni 2023 (PMID 36241197) recommends integration but does not provide a validated composite.

References

  1. Frazzoni L, et al. Clinical value of alarm features for colorectal cancer: a meta-analysis. Endoscopy. 2023;55(5):458-468. PMID 36241197
  2. Tong GX, et al. Diagnostic value of rectal bleeding in predicting colorectal cancer: a systematic review. Asian Pac J Cancer Prev. 2014;15(2):1015-21. PMID 24568444
  3. Asghar Z, et al. Diagnostic Yield of Colonoscopy in Patients With Symptoms Compatible With Rome IV Functional Bowel Disorders. Clin Gastroenterol Hepatol. 2022;20(2):334-341.e3. PMID 32882424
  4. Wu J, Wang C, Lv L. Diagnostic yield of colonoscopy for organic disease in irritable bowel syndrome and its risk factors: A meta-analysis. Neurogastroenterol Motil. 2023;35(2):e14481. PMID 36168183
  5. Staller K, et al. Diagnostic yield of endoscopy in irritable bowel syndrome: A nationwide prevalence study 1987-2016. Eur J Intern Med. 2021;94:85-92. PMID 34420846
  6. Shiha MG, et al. Global Prevalence of Celiac Disease in Patients With Rome III and Rome IV Irritable Bowel Syndrome. Am J Gastroenterol. 2025;120(12):2776-2787. PMID 40493044
  7. Slattery SA, Niaz O, Aziz Q, Ford AC, Farmer AD. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 2015;42(1):3-11. PMID 25913530
  8. Dilmaghani S, et al. Meta-Analysis: Efficacy and Safety of Sequestrants for Bile Acid Diarrhoea. Aliment Pharmacol Ther. 2025;62(11-12):1054-1065. PMID 41090475
  9. Leeds JS, et al. Some patients with irritable bowel syndrome may have exocrine pancreatic insufficiency. Clin Gastroenterol Hepatol. 2010;8(5):433-8. PMID 19835990
  10. Olmos JI, et al. Exocrine Pancreatic Insufficiency is Undiagnosed in Some Patients with Diarrhea-Predominant Irritable Bowel Syndrome Using the Rome IV Criteria. Dig Dis Sci. 2022;67(12):5666-5675. PMID 35704255
  11. Shin A, Xu H, Sarnoff R, Church A, Chang L. Research Communication: An Observational Cohort Study on Risk of Ovarian Cancer in Women with Irritable Bowel Syndrome. Aliment Pharmacol Ther. 2025;62(9):944-947. PMID 41081454
  12. Maconi G, et al. The impact of symptoms, irritable bowel syndrome pattern and diagnostic investigations on the diagnostic delay of Crohn's disease. Dig Liver Dis. 2015;47(8):646-51. PMID 26004215
  13. Camilleri M. When and What to Test for Diarrhea: Focus on Stool Testing. Am J Gastroenterol. 2025;120(4):778-784. PMID 39480027
  14. Hanevik K, et al. Irritable bowel syndrome and chronic fatigue 6 years after giardia infection. Clin Infect Dis. 2014;59(10):1394-400. PMID 25115874
  15. Black CJ, Ford AC. Rational investigations in irritable bowel syndrome. Frontline Gastroenterol. 2020;11(2):140-147. PMID 32133113
  16. Engsbro AL, et al. A positive diagnostic strategy is safe and saves endoscopies in patients with irritable bowel syndrome: A five-year follow-up of a randomized controlled trial. Neurogastroenterol Motil. 2021;33(3):e14004. PMID 33029843
  17. Longstreth GF. Avoiding unnecessary surgery in irritable bowel syndrome. Gut. 2007;56(5):608-10. PMID 17440179
  18. Cash BD, Lacy BE, Schoenfeld PS, Dove LS, Covington PS. Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea. Am J Gastroenterol. 2017;112(2):365-374. PMID 27922029
  19. Lembo AJ, et al. Eluxadoline for Irritable Bowel Syndrome with Diarrhea. N Engl J Med. 2016;374(3):242-53. PMID 26789872
  20. Gawron AJ, Bielefeldt K. Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome With Eluxadoline. Clin Gastroenterol Hepatol. 2018;16(3):378-384.e2. PMID 28804032
  21. Brenner DM, et al. Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study. Am J Gastroenterol. 2019;114(9):1502-1511. PMID 31356229
  22. Lewis JH. Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective. Expert Rev Gastroenterol Hepatol. 2010;4(1):13-29. PMID 20136586
  23. Lucak SL. Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome. Therap Adv Gastroenterol. 2010;3(3):165-72. PMID 21180598
  24. Lacy BE, Brenner DM, Chey WD. Re-evaluation of the Cardiovascular Safety Profile of Tegaserod. Clin Gastroenterol Hepatol. 2022;20(4):e682-e695. PMID 34048937
  25. Busam JA, et al. The Safety of Pharmacotherapy for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2026;121(3):745-753. PMID 40471839
  26. Chey WD, Lembo AJ, Yang Y, Rosenbaum DP. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation (T3MPO-2). Am J Gastroenterol. 2021;116(6):1294-1303. PMID 33337659
  27. Chey WD, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol. 2012;107(11):1702-12. PMID 22986437
  28. Black CJ, et al. Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2020;5(2):117-131. PMID 31859183
  29. Wright-Hughes A, et al. Low-dose titrated amitriptyline as second-line treatment for adults with irritable bowel syndrome in primary care: the ATLANTIS RCT. Health Technol Assess. 2024;28(66):1-161. PMID 39397570
  30. Pimentel M, et al. Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity. Dig Dis Sci. 2017;62(9):2455-2463. PMID 28589238
  31. Corsetti M, Pannemans J, Whorwell P. Targeting mu opioid receptors to modulate gastrointestinal function: what have we learnt so far from the studies in functional bowel disorders? F1000Res. 2019;8:F1000. PMID 30863534
  32. Hughes PA, Costello SP, Bryant RV, Andrews JM. Opioidergic effects on enteric and sensory nerves in the lower GI tract: basic mechanisms and clinical implications. Am J Physiol Gastrointest Liver Physiol. 2016;311(3):G501-13. PMID 27469369
  33. Lin YM, et al. An opioid receptor-independent mechanism underlies motility dysfunction and visceral hyperalgesia in opioid-induced bowel dysfunction. Am J Physiol Gastrointest Liver Physiol. 2021;320(6):G1093-G1104. PMID 33908261
  34. Fukudo S, et al. Centrally Mediated Disorders of Gastrointestinal Pain. Gastroenterology. 2026;170(6):1283-1302. PMID 41692277
  35. Keefer L, et al. Centrally Mediated Disorders of Gastrointestinal Pain. Gastroenterology. 2016. PMID 27144628
  36. Wilson B, et al. β-Galactooligosaccharide in Conjunction With Low FODMAP Diet Improves Irritable Bowel Syndrome Symptoms but Reduces Fecal Bifidobacteria. Am J Gastroenterol. 2020;115(6):906-915. PMID 32433273
  37. Halmos EP, et al. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut. 2015;64(1):93-100. PMID 25016597
  38. O'Keeffe M, et al. Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome. Neurogastroenterol Motil. 2018;30(1). PMID 28707437
  39. Scarlata K, et al. A Call to Action: Unraveling the Nuance of Adapted Eating Behaviors in Individuals With Gastrointestinal Conditions. Clin Gastroenterol Hepatol. 2025;23(6):893-901.e2. PMID 39681226
  40. Atkins M, et al. Assessment and management of disorders of gut-brain interaction in patients with eating disorders. J Eat Disord. 2023;11:20. PMID 36782302
  41. Pop A, et al. Self-Perceived Lactose Intolerance Versus Confirmed Lactose Intolerance in Irritable Bowel Syndrome: A Systematic Review. J Gastrointestin Liver Dis. 2024 Sep 9 (online ahead of print). PMID 39255349
  42. Van den Houte K, et al. Efficacy and Findings of a Blinded Randomized Reintroduction Phase for the Low FODMAP Diet in Irritable Bowel Syndrome. Gastroenterology. 2024;167(2):333-342. PMID 38401741
  43. Miller V, Hopkins L, Whorwell PJ. Suicidal ideation in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2004;2(12):1064-8. PMID 15625650
  44. Li H, et al. Associations Between Irritable Bowel Syndrome, Depression, Anxiety, and Suicidal Ideation: a Partial Least Squares Path Analysis. Psychiatr Q. 2026 Apr 25 (online ahead of print). PMID 42034841
  45. Deng Z, et al. Causality Between Irritable Bowel Syndrome and Suicide Attempt: A Mendelian Randomization Study. Brain Behav. 2025;15(5):e70513. PMID 40320944
  46. Wileman V, et al. Development and preliminary evaluation of a suicidal risk assessment protocol in a randomised controlled trial using the Patient Health Questionnaire (PHQ-9). Trials. 2024;25:476. PMID 38997767
  47. Ford AC, et al. Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS). Lancet. 2023;402(10414):1773-1785. PMID 37858323
  48. Bontempo AC, Bontempo JM, Duberstein PR. Ignored, dismissed, and minimized: Understanding the harmful consequences of invalidation in health care. Psychol Bull. 2025;151(4):399-427. PMID 40310228
  49. Klem F, et al. Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis. Gastroenterology. 2017;152(5):1042-1054.e1. PMID 28069350